[go: up one dir, main page]

WO2005000245A3 - Compositions and methods for increasing telomerase activity - Google Patents

Compositions and methods for increasing telomerase activity Download PDF

Info

Publication number
WO2005000245A3
WO2005000245A3 PCT/US2004/020277 US2004020277W WO2005000245A3 WO 2005000245 A3 WO2005000245 A3 WO 2005000245A3 US 2004020277 W US2004020277 W US 2004020277W WO 2005000245 A3 WO2005000245 A3 WO 2005000245A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
telomerase activity
cells
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/020277
Other languages
French (fr)
Other versions
WO2005000245A2 (en
Inventor
Calvin B Harley
Allison C Chin
Tsutomu Akama
Nancy Yuk-Yu Ip
Yung-Hou Wong
David M Miller-Martini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0411856-1A priority Critical patent/BRPI0411856A/en
Priority to CN2004800172464A priority patent/CN1809364B/en
Priority to US10/562,374 priority patent/US7846904B2/en
Priority to EA200600076A priority patent/EA009442B1/en
Priority to HRP20180330TT priority patent/HRP20180330T1/en
Priority to KR1020137031630A priority patent/KR101465515B1/en
Priority to CA2528483A priority patent/CA2528483C/en
Priority to ES04777032.6T priority patent/ES2666864T3/en
Priority to EP04777032.6A priority patent/EP1644009B1/en
Priority to AU2004251753A priority patent/AU2004251753C1/en
Priority to NZ544191A priority patent/NZ544191A/en
Priority to AP2005003474A priority patent/AP2280A/en
Priority to SI200432425T priority patent/SI1644009T1/en
Priority to EP12180710.1A priority patent/EP2548880B1/en
Priority to KR1020057024720A priority patent/KR101312389B1/en
Application filed by Geron Corp filed Critical Geron Corp
Priority to LTEP04777032.6T priority patent/LT1644009T/en
Priority to DK04777032.6T priority patent/DK1644009T3/en
Priority to PL04777032T priority patent/PL1644009T3/en
Priority to PL12180710T priority patent/PL2548880T3/en
Priority to JP2006517617A priority patent/JP5583882B2/en
Priority to MXPA05013844A priority patent/MXPA05013844A/en
Publication of WO2005000245A2 publication Critical patent/WO2005000245A2/en
Publication of WO2005000245A3 publication Critical patent/WO2005000245A3/en
Anticipated expiration legal-status Critical
Priority to US12/718,812 priority patent/US8759304B2/en
Priority to US14/313,698 priority patent/US20150093455A1/en
Priority to CY20181100225T priority patent/CY1119951T1/en
Priority to CY20191100342T priority patent/CY1121447T1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin aliments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells.
PCT/US2004/020277 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity Ceased WO2005000245A2 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
KR1020057024720A KR101312389B1 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
US10/562,374 US7846904B2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
EA200600076A EA009442B1 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
HRP20180330TT HRP20180330T1 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
KR1020137031630A KR101465515B1 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
CA2528483A CA2528483C (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
ES04777032.6T ES2666864T3 (en) 2003-06-23 2004-06-23 Compositions to increase telomerase activity and treat HIV infection
EP04777032.6A EP1644009B1 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
AU2004251753A AU2004251753C1 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
NZ544191A NZ544191A (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
AP2005003474A AP2280A (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomeraseactivity.
SI200432425T SI1644009T1 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
EP12180710.1A EP2548880B1 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity
BRPI0411856-1A BRPI0411856A (en) 2003-06-23 2004-06-23 compositions and methods for increasing telomerase activity
JP2006517617A JP5583882B2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
LTEP04777032.6T LT1644009T (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
DK04777032.6T DK1644009T3 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating HIV infection
PL04777032T PL1644009T3 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity and treating hiv infection
PL12180710T PL2548880T3 (en) 2003-06-23 2004-06-23 Compositions for increasing telomerase activity
CN2004800172464A CN1809364B (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
MXPA05013844A MXPA05013844A (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity.
US12/718,812 US8759304B2 (en) 2003-06-23 2010-03-05 Compositions and methods for increasing telomerase activity
US14/313,698 US20150093455A1 (en) 2003-06-23 2014-06-24 Compositions and methods for increasing telomerase activity
CY20181100225T CY1119951T1 (en) 2003-06-23 2018-02-26 COMPOSITIONS FOR INCREASING TELOMERASING ACTIVITY AND TREATMENT OF HIV INFECTION
CY20191100342T CY1121447T1 (en) 2003-06-23 2019-03-22 COMPOSITIONS FOR INCREASING TELEVISION ACTIVITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23
US60/480,988 2003-06-23

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/562,374 A-371-Of-International US7846904B2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity
US12/718,812 Division US8759304B2 (en) 2003-06-23 2010-03-05 Compositions and methods for increasing telomerase activity
US12/718,812 Continuation US8759304B2 (en) 2003-06-23 2010-03-05 Compositions and methods for increasing telomerase activity

Publications (2)

Publication Number Publication Date
WO2005000245A2 WO2005000245A2 (en) 2005-01-06
WO2005000245A3 true WO2005000245A3 (en) 2005-05-26

Family

ID=33551962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/020277 Ceased WO2005000245A2 (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomerase activity

Country Status (24)

Country Link
US (3) US7846904B2 (en)
EP (2) EP2548880B1 (en)
JP (4) JP5583882B2 (en)
KR (3) KR20110089887A (en)
CN (1) CN1809364B (en)
AP (1) AP2280A (en)
AU (2) AU2004251753C1 (en)
BR (1) BRPI0411856A (en)
CA (1) CA2528483C (en)
CY (2) CY1119951T1 (en)
DK (2) DK2548880T3 (en)
EA (1) EA009442B1 (en)
ES (2) ES2666864T3 (en)
HR (2) HRP20180330T1 (en)
HU (2) HUE036559T2 (en)
LT (2) LT1644009T (en)
MX (1) MXPA05013844A (en)
NZ (1) NZ544191A (en)
PL (2) PL2548880T3 (en)
PT (2) PT2548880T (en)
SI (2) SI1644009T1 (en)
TR (2) TR201802543T4 (en)
WO (1) WO2005000245A2 (en)
ZA (1) ZA200509846B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
ZA200509846B (en) * 2003-06-23 2007-04-25 Geron Corp Compositions and methods for increasing telomerase activity
WO2005000248A2 (en) * 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (en) * 2005-09-08 2007-08-29 南京医科大学 Application of astragaloside in preparing medication for treating peripheral nervous lesion of diabetes
CN100384830C (en) * 2006-01-12 2008-04-30 天津药物研究院 Derivative of cyclo membranousol kind and application thereof
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
PL2101789T3 (en) 2006-10-30 2015-05-29 Geron Corp Combined telomerase inhibitor and gemcitabine for the treatment of cancer
EA021544B1 (en) 2007-06-04 2015-07-30 Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити TRIARY AREAS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CN101225424B (en) 2007-09-13 2013-05-29 天津药物研究院 Single-glucopyranoside of cyclomembranousol, preparation method, medicament combination and uses thereof
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
CA2795981C (en) * 2009-05-18 2017-06-27 Geron Corporation Compositions and methods for increasing telomerase activity
CA2912698A1 (en) * 2013-05-15 2014-11-20 Fybrands Corp. Compositions for improving the hair, skin, and nails
AU2014347668A1 (en) 2013-11-05 2016-05-19 Ben-Gurion University Of The Negev Research And Development Authority Compounds for the treatment of diabetes and disease complications arising from same
CN104435370A (en) * 2014-12-06 2015-03-25 王香平 Health wine for treating rheumatism
CN104491185A (en) * 2014-12-06 2015-04-08 郭亮 Rheumatism-eliminating medicinal liquor and preparation method thereof
CN104435371A (en) * 2014-12-06 2015-03-25 郭亮 Medicated wine for treating arthritis
KR20160069857A (en) 2014-12-09 2016-06-17 (주)스피어테크 Compositions and methods for increasi ng telomere activity
CN104817610A (en) * 2015-03-15 2015-08-05 北京化工大学 Method for preparation of Cycloastragenol by sulfuric acid hydrolysis
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
SG10201902872YA (en) 2015-04-03 2019-04-29 Propagenix Inc Ex vivo proliferation of epithelial cells
CN106474094A (en) * 2015-08-31 2017-03-08 南京理工大学 A kind of Cycloastragenol electrospun fiber membrane and preparation method thereof
EP3347450B1 (en) 2015-09-11 2021-03-17 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106307522A (en) * 2016-11-06 2017-01-11 谭淞文 Anti-aging health-care product as well as preparation method and eating method thereof
CN106831927B (en) * 2017-02-07 2018-02-09 江西师范大学 A kind of synthetic method of Astragaloside IV
CN108498521B (en) * 2017-02-24 2020-05-05 北京大学 Application of cycloastragenol in preparation of medicine for inhibiting abdominal aortic aneurysm
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
WO2020028055A1 (en) * 2018-07-31 2020-02-06 ADLER, Benjamin, Aaron Ophthalmic formulations and uses thereof
KR102655940B1 (en) 2018-08-13 2024-04-11 (주)아모레퍼시픽 Novel ginsenoside, and anti-imflammantory composition comprising the same
CN111053782B (en) 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 Composition containing ginsenoside
KR102635196B1 (en) 2018-10-17 2024-02-13 (주)아모레퍼시픽 Skin brightening composition comprising novel ginsenoside
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (en) * 2018-12-20 2020-06-25 Muhammed Majeed Telomerase enhancement potential of ecdysterone
CN109942663B (en) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 Method for preparing cycloastragenol by using diphasic acid hydrolysis
MX2019006749A (en) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Cellular senescence activating compounds.
KR102842908B1 (en) 2019-09-27 2025-08-07 (주)아모레퍼시픽 Composition for improving skin elasticity comprising novel ginsenoside
KR102842907B1 (en) 2019-09-27 2025-08-07 (주)아모레퍼시픽 Composition for preventing or improving menopausal symptom comprising novel ginsenoside
CN111419854B (en) * 2020-05-18 2021-03-30 南通大学 Application of triterpene with special seven-membered ring structure in preparation of medicine for preventing and treating nerve injury
US12305233B1 (en) 2020-07-09 2025-05-20 Arizona Board Of Regents On Behalf Of Arizona Ultra-high-throughput assay for telomerase repeat addition processivity
CN113480628B (en) * 2021-08-17 2022-06-21 贵州师范大学 Guizhou wart mud eel polypeptide TK-CATH and coding gene and application thereof
CN113968894B (en) * 2021-11-05 2024-05-28 山西大学 A method for preparing cycloastragenol by degradation of astragaloside IV
KR102666469B1 (en) * 2023-05-04 2024-05-17 주식회사 아리바이오 Composition for drug delivery comprising nanoparticle carrying telomerase activator and composition for preventing, improving or treating hair loss
CN119818509B (en) * 2025-02-10 2025-10-17 山西中医药大学 Application of astragalool in preparing products for treating or alleviating Parkinson's disease
CN120137936A (en) * 2025-03-14 2025-06-13 北京娅熙妍国际贸易有限公司 Telomerase variants and their application in anti-aging

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770578A (en) * 1994-03-16 1998-06-23 Bergi Gmbh Use of triterpensaponins, such as notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for preparing medicaments

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212792A (en) * 1986-07-18 1987-01-21 Osaka Chem Lab Isolation of astragali radix saponin
JPS6212791A (en) * 1986-07-18 1987-01-21 Osaka Chem Lab Astragali radix saponin, isolation and use thereof
IT1259645B (en) 1992-04-10 1996-03-25 Solis Srl METHOD FOR DETECTING THE DENSITY CHANGE OF A FABRIC AND DEVICE FOR ITS IMPLEMENTATION
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (en) 1992-09-17 1994-12-02 Lvmh Rech Gie Cosmetic or dermatological composition containing at least one ginsenoside-type saponin, and its applications, in particular for hair care.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (en) * 1994-02-25 1995-09-12 Pola Chem Ind Inc Arteriosclerosis inhibitor and food or medicine containing the same
ATE308554T1 (en) * 1994-07-07 2005-11-15 Geron Corp MAMMAL TELOMERASE
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US6162459A (en) 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (en) 1995-08-01 2002-02-20 裴国增 Lucid ganoderma oral liquid and preparation process
US5785977A (en) 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (en) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd Synthesis inhibitor containing ginsenoside of protein belonging to hsp 27 family
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
FI990655A7 (en) 1996-10-01 1999-06-01 Geron Corp Catalytic subunit of human telomerase
DK0988044T3 (en) 1997-01-28 2008-05-13 Amelio Frank D Water / ethanol plant extract of Centipeda cunninghamii
US5786343A (en) 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
AU748441B2 (en) 1997-09-05 2002-06-06 Procter & Gamble Company, The Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients
KR100481563B1 (en) 1997-09-12 2005-04-08 더 프록터 앤드 갬블 캄파니 Cleansing and conditioning article for skin or hair
WO1999035243A2 (en) 1998-01-12 1999-07-15 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
AU5338199A (en) 1998-08-09 2000-02-28 Geron Corporation Methods and compositions for inhibiting or stimulating telomerase assembly
AU2156600A (en) 1998-11-25 2000-06-13 Cold Spring Harbor Laboratory Methods and reagents for increasing proliferative capacity and preventing replicative senescence
JP2000204091A (en) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd New benzodioxole derivatives
JP2000229827A (en) * 1999-02-05 2000-08-22 Kose Corp Skin lotion
JP2000229834A (en) * 1999-02-10 2000-08-22 Kanebo Ltd Cosmetic
AUPQ127399A0 (en) 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
JP2001258505A (en) * 2000-03-24 2001-09-25 Fancl Corp Food composition
CA2307393A1 (en) * 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
US6277396B1 (en) 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
EP1295893A4 (en) 2000-05-31 2005-10-26 Japan Science & Tech Agency GINSENOSIDES FOR PROMOTING SKIN WEBERENEGENERATION
CN1172677C (en) * 2000-07-14 2004-10-27 复旦大学附属中山医院 Application of astragaloside IV in preparation of pharmaceutical composition
WO2002007732A2 (en) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Use of panaxatriol for stimulation angiogenesis
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
US6696094B2 (en) 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (en) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 Immunoregulator for resisting I-type allergic reaction and its preparing process
CN1369276A (en) 2001-02-12 2002-09-18 徐秀荣 Composition and method for effectively losing body weight
JP2002275086A (en) * 2001-03-15 2002-09-25 Fancl Corp Composition for improving frail constitution
US7262174B2 (en) 2001-05-09 2007-08-28 Geron Corporation Treatment for wounds
US20020182272A1 (en) 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP2003089687A (en) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd Novel butadiene derivative, its production method and its synthetic intermediate
US20040180938A1 (en) 2001-07-03 2004-09-16 Akio Ohtani Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof
US20030108629A1 (en) 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US6855344B2 (en) 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (en) * 2001-08-31 2004-09-01 上海中医药大学 Astragaloside A with anti-myocardial fibrosis
CN1406585A (en) 2001-09-07 2003-04-02 中国科学院上海药物研究所 Medicinal composition for viral myocarditis
JP2003160497A (en) * 2001-11-22 2003-06-03 Toshin Kagaku Kk Skin care preparation
AU2003212936A1 (en) 2002-02-04 2003-09-02 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
CN1236803C (en) 2002-03-20 2006-01-18 郑国芃 Rheuamtism treating Chinese medicine
CN1189176C (en) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 Astragalus root methyl-glycoside composition and preparation method
WO2004096251A1 (en) * 2003-03-26 2004-11-11 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
ZA200509846B (en) 2003-06-23 2007-04-25 Geron Corp Compositions and methods for increasing telomerase activity
WO2005000248A2 (en) 2003-06-25 2005-01-06 Geron Corporation Compositions and methods for skin conditioning
US20070122501A1 (en) 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770578A (en) * 1994-03-16 1998-06-23 Bergi Gmbh Use of triterpensaponins, such as notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for preparing medicaments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase

Also Published As

Publication number Publication date
AP2005003474A0 (en) 2005-12-31
LT2548880T (en) 2019-03-25
EA200600076A1 (en) 2006-08-25
CN1809364B (en) 2010-06-16
KR20110089887A (en) 2011-08-09
TR201802543T4 (en) 2018-03-21
MXPA05013844A (en) 2006-07-06
ES2666864T3 (en) 2018-05-08
EP2548880A2 (en) 2013-01-23
CA2528483C (en) 2012-04-10
KR101465515B1 (en) 2014-11-26
CN1809364A (en) 2006-07-26
HUE043168T2 (en) 2019-08-28
CY1119951T1 (en) 2018-12-12
US8759304B2 (en) 2014-06-24
AU2004251753A1 (en) 2005-01-06
US20150093455A1 (en) 2015-04-02
EP1644009A4 (en) 2010-04-07
PT2548880T (en) 2019-02-27
DK1644009T3 (en) 2018-03-05
PL2548880T3 (en) 2019-07-31
JP5841337B2 (en) 2016-01-13
JP2011098991A (en) 2011-05-19
JP5583882B2 (en) 2014-09-03
JP2007524627A (en) 2007-08-30
AU2004251753C1 (en) 2009-04-09
ZA200509846B (en) 2007-04-25
JP5913253B2 (en) 2016-04-27
SI1644009T1 (en) 2018-04-30
EP2548880B1 (en) 2019-01-09
PL1644009T3 (en) 2018-07-31
CA2528483A1 (en) 2005-01-06
EP2548880A3 (en) 2013-06-19
AU2008249200A1 (en) 2008-12-18
CY1121447T1 (en) 2020-05-29
NZ544191A (en) 2008-12-24
AP2280A (en) 2011-10-31
BRPI0411856A (en) 2006-08-29
DK2548880T3 (en) 2019-04-08
KR20130137252A (en) 2013-12-16
JP2016041770A (en) 2016-03-31
TR201903587T4 (en) 2019-04-22
KR20060034237A (en) 2006-04-21
HUE036559T2 (en) 2018-07-30
PT1644009T (en) 2018-02-28
HRP20190322T1 (en) 2019-04-19
EP1644009B1 (en) 2017-11-29
LT1644009T (en) 2018-03-12
EP1644009A2 (en) 2006-04-12
EA009442B1 (en) 2007-12-28
HRP20180330T1 (en) 2018-04-20
US7846904B2 (en) 2010-12-07
US20080113925A1 (en) 2008-05-15
SI2548880T1 (en) 2019-04-30
JP2014024861A (en) 2014-02-06
ES2716528T3 (en) 2019-06-13
KR101312389B1 (en) 2013-09-27
AU2004251753B2 (en) 2008-11-20
US20110071095A1 (en) 2011-03-24
WO2005000245A2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2005044179A3 (en) Formulations containing astragalus extracts and uses thereof
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
WO2010085039A3 (en) Noggin-derived peptide and use thereof
WO2006123248A3 (en) Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject
UA99167C2 (en) Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells
MY143795A (en) Tetrahydropyridoindole derivatives
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2004047747A3 (en) Compositions and methods for cell dedifferentiation and tissue regeneration
WO2008058547A3 (en) Alpha-lactalbumin composition
EP1658853A4 (en) TREATMENT OF INTERNALLY ADMINISTERED CRANIAL NERVE DISEASES CONTAINING THE ACTIVE INGREDIENT OF MESENCHYMAL CELLS
BR112013005673A2 (en) use of lysosomal acid lipase for treatment of lysosomal acid lipase deficiency in patients
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
BRPI0418157A (en) allogeneic tumor therapy
IL173369A (en) Combined pharmaceutical preparation containing g - csf and p1gf effective in stimulating mobilization of peripheral blood progenitor cells
ZA200701798B (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalioproteinases inhibitors
WO2003039591A3 (en) Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2006116185A3 (en) Methods for the treatment of multiple myeloma
WO2005123651A8 (en) L-2-(α-HYDROXYPENTYL)BENZOATES, THE PREPARATION AND THE USE THEREOF
WO2006023623A3 (en) Methods of healing wounds by administering human il-18
AU2002333536A1 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
SI1596879T1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 5605/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2005/09846

Country of ref document: ZA

Ref document number: 200509846

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2528483

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004251753

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 544191

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/013844

Country of ref document: MX

Ref document number: 2006517617

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20048172464

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1020057024720

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: AP/P/2005/003474

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 2004251753

Country of ref document: AU

Date of ref document: 20040623

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004251753

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200600076

Country of ref document: EA

REEP Request for entry into the european phase

Ref document number: 2004777032

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004777032

Country of ref document: EP

Ref document number: 1200600120

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 2004777032

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057024720

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0411856

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 10562374

Country of ref document: US